EXPERIMENTAL RATIONALE FOR THE ENDOTHELIAL PROTECTIVE EFFECT OF INTRAVENOUS IMMUNOGLOBULINS IN OBSTETRIC DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the cytoprotective effect of intravenous immunoglobulins (IVIGs) against endothelial cells. Subjects and methods. The cytotoxic effects of the sera obtained from 45 pregnant women against the endothelial cells treated with IVIGs were investigated using culture, an enzyme immunoassay, and flow cytometry. Results. After treatment of endothelial cells with IVIGs, there was a reduction in the cytotoxic effect of the sera obtained from the women with recurrent miscarriage against endothelial cells. Conclusion. IVIGs are effective cytoprotectors that are able to prevent abnormalities associated with endothelial damage and dysfunction.

Full Text

Restricted Access

About the authors

Sergey Vladimirovich Chepanov

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: chepanovsv@gmail.com
laboratory doctor, laboratory of immunology Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Dmitry Igorevich Sokolov

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: falcojugger@yandex.ru
Doctor of biological sciences, leading researcher Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Tatiana Nikolaevna Shlachtenko

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: tatnicshl@mail.ru
MD, Senior Researcher, Laboratory of Immunology Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Roman Viktorovich Kapustin

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: kapustin.Roman@gmail.com
MD, Obstetrician gynecologist Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Larisa Sergeevna Okorokova

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: larisaok123@gmail.com
researcher of the laboratory of immunology Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Ksenia Lvovna Belyakova

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: kseniyabelyakova129@gmail.com
researcher of the laboratory of immunology Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

Sergey Alekseevich Selkov

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: selkovsa@mail.ru
Doctor of medical sciences, head of the laboratory of immunology Saint Petersburg 199034, Mendeleyevskaya line 3, Russia

References

  1. Сидельникова В.М. Подготовка и ведение беременности у женщин с привычным невынашиванием. 3-е изд. М.: МЕДпресс-информ; 2013. 224с.
  2. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра; 2006. 440с.
  3. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011; 7(6): 330-9.
  4. Riboldi P., Gerosa M., Raschi E., Testoni C., Meroni P.L. Endothelium as a target for antiphospholipid antibodies. Immunobiology. 2003; 207(1): 29-36.
  5. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P. et al.Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998; 91(10): 3527-61.
  6. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ. Res. 2002; 90(1): 29-37.
  7. Meroni P.L., Raschi E., Testoni C., Borghi M.O. Endothelial cell activation by antiphospholipid antibodies. Clin. Immunol. 2004; 112(2): 169-74.
  8. Коноплева Л.Ф. Эндотелиальная дисфункция в патогенезе сердечно-сосудистых заболеваний и методы ее коррекции. Therapia. 2011; 3: 26-30.
  9. Vlachoyiannopoulos P. G., Routsias J.G. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J. Autoimmun. 2010; 35(3): 248-55.
  10. Bertsias G., Ioannidis J.P.A., Boletis J., Bombardieri S., Cervera R., Dostal C. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 2008; 67(2): 195-205.
  11. Danza A., Ruiz-Irastorza G., Khamashta M. Antiphospohlipid syndrome in obstetrics. Best Pract. Res. Clin. Obstet. Gynaecol. 2012; 26(1): 65-76.
  12. Stephenson M.D., Kutteh W.H., Purkiss S., Librach C., Schultz P., Houlihan E., Liao C. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum. Reprod. 2010; 25(9): 2203-9.
  13. Ensom M.H., Stephenson M.D. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum. Reprod. 2011; 26(9): 2283-8.
  14. Ronda N., Bernini F., Giacosa R., Gatti R., Baldini N., Buzio C., Orlandini G. Normal human IgG prevents endothelial cell activation induced by TNF a and oxidized low-density lipoprotein atherogenic stimuli. Clin. Exp. Immunol. 2003; 133(2): 219-26.
  15. Ушкалова Е.А., Шифман Е.М. Проблема нерегламентированного применения иммуноглобулина для внутривенного введения в акушерстве. Акушерство и гинекология. 2011; 3: 74-80.
  16. Christiansen O.B., Larsen E.C., Egerup P., Lunoee L., Egestad L., Nielsen H.S. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. BJOG. 2015; 122(4): 500-8.
  17. Hutton B., Sharma R., Fergusson D., Tinmouth A., Hebert P., Jamieson J., Walker M. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG. 2007; 114(2): 134-42.
  18. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J, Danowski A. et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun. Rev. 2014; 13(6): 685-696.
  19. Meroni P.L., Tedesco F., Locati M., Vecchi A., Di Simone N., Acaia B. et al.Antiphospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus. 2010; 19(4): 453-6.
  20. Pan L.F., Kreisle R.A., Shi Y.D. Detection of Fc gamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma ( IFN- gamma). Clin. Exp. Immunol. 1998; 112(3): 533-8.
  21. Devaraj S., Davis B., Simon S.I., Jialal I. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am. J. Physiol. Heart Circ. Physiol. 2006; 291(3): H1170-6.
  22. D’Ippolito S., Di Simone N., Di Nicuolo F., Castellani R., Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am. J. Reprod. Immunol. 2007; 58(2): 150-8.
  23. Rand J.H., Wolgast L.R. Dos and don’ts in diagnosing antiphospholipid syndrome. Hematology Am. Soc. Hematol. Educ. Program. 2012; 2012: 455-9.
  24. Moraru M., Carbone J., Alecsandru D., Castillo-Rama M., García-Segovia A., Gil J. et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. Am. J. Reprod. Immunol. 2012; 68(1): 75-84.
  25. Christiansen O.B., Pedersen B., Rosgaard A., Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum. Reprod. 2002; 17(3): 809-16.
  26. Wong L.F., Porter T.F., Scott J.R. Immunotherapy for recurrent miscarriage (Review ). Cochrane Database Syst. Rev. 2014; (10: CD000112.
  27. Чугунова А.А., Зайнулина М.С., Селютин А.В., Соколов Д.И., Михайлова В.А., Чепанов С.В., Сельков С.А. Содержание основных субпопуляций иммуно компетентных клеток у беременных с невынашиванием и антифосфолипидным синдромом при лечении препаратами иммуноглобулинов. Акушерство и гинекология. 2012; 2: 30-5.
  28. Michiels C. Endothelial cell functions. J. Cell. Physiol. 2003; 196(3): 430-43.
  29. Lima M.V.S., Duek E.A.R., Santana C.C. Adsorption of human immunoglobulin G to poly ( β-hydroxybutyrate) (PHB), poly (L- lactic Acid) (PLLA) and PHB/PLLA blends. Braz. J. Chem. Eng. 2009; 26(2): 257-64.
  30. Gill V., Doig C., Knight D., Love E., Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation. 2005; 112(13): 2031-9.
  31. Arumugam T.V., Tang S.C., Lathia J.D.,Cheng A., Mughal M.R., Chigurupati S. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl. Acad. Sci. USA. 2007; 104(35): 14104-9.
  32. Ronda N., Gatti R., Orlandini G., Borghetti A. Binding and internalization of human IgG by living cultured endothelial cells. Clin. Exp. Immunol. 1997; 109(1): 211-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies